Concord Biotech Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹326.08 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.39 per cent from ₹277.77 crore. This corresponds to a year-on-year *(YoY) decline of 24.15 per cent.
Operating Profit
Operating Profit stands at ₹118.35 crore, reflecting a quarter-on-quarter *(QoQ) increase of 24.57 per cent from ₹95.01 crore. This corresponds to a year-on-year *(YoY) decline of 37.34 per cent.
PBDT
PBDT stands at ₹133.62 crore, reflecting a quarter-on-quarter *(QoQ) increase of 27.37 per cent from ₹104.91 crore. This corresponds to a year-on-year *(YoY) decline of 32.57 per cent.
Profit Before Tax
Profit Before Tax stands at ₹114.08 crore, reflecting a quarter-on-quarter *(QoQ) increase of 32.40 per cent from ₹86.16 crore. This corresponds to a year-on-year *(YoY) decline of 37.85 per cent.
Net Profit
Net Profit stands at ₹88.47 crore, reflecting a quarter-on-quarter *(QoQ) increase of 39.02 per cent from ₹63.64 crore. This represents a 36.98 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Concord Biotech Ltd News
Concord Biotech Ltd Earnings
- YOY
- QOQ
Concord Biotech Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Concord Biotech Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Concord Biotech Ltd Financial Reports
Concord Biotech Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Concord Biotech | 3.39% | 6.03% | -2.37% | 29.48% | -0.16% | -26.51% |
| Alembic Pharma | -0.81% | -0.04% | 12.46% | 13.02% | 5.25% | -19.38% |
| Jubilant Pharmo | 1.06% | -0.40% | -2.11% | 7.23% | -8.86% | -18.64% |
| Alivus Life | 0.29% | 1.57% | 10.68% | 9.12% | 31.15% | 8.42% |
| Viyash Scientific | 2.12% | 1.88% | 13.79% | 35.29% | 47.09% | 53.44% |
| Corona Remedies | -0.72% | 1.68% | 17.05% | 28.47% | 37.15% | 40.69% |
| Shilpa Medicare | 0.60% | 5.10% | 18.49% | 52.14% | 114.38% | 39.31% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : SUDHIR JAIRAM VAID
ED / Joint MD / CEO / Promoter : ANKUR VAID
Non Executive Director : Ravi Kapoor
Non Executive Director : Rajiv Agarwal
Independent Non Exe. Director : BHARTI KHANNA
Independent Non Exe. Director : Amitabh Thakore
Independent Non Exe. Director : Arvind Agarwal
Independent Non Exe. Director : Jayaram Easwaran
Independent Non Exe. Director : Mandayam Chakravarthy Sriraman
Company Sec. & Compli. Officer : Hina Ronak Patel